Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Tzeng, Huey En ^a,b   Lin, Cheng Li ^a,c   Tsai, Chun Hao ^a,c   Tang, Chih Hsin ^a   Hwang, Wen Li ^b   Cheng, Ya Wen ^d   Sung, Fung Chang ^a,c   Chung, Chi Jung ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; POPULATION RESEARCH; RISK FACTOR; SECOND CANCER; SEX DIFFERENCE; TAIWAN; TREND STUDY;

AGE FACTORS; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84879768294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068041     Document Type: Article

References (38)

1. Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, et al. (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118: 1239-1247.
2. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. George ED, Sadovsky R, (1999) Multiple myeloma: recognition and management. Am Fam Physician 59: 1885-1894.
4. Turesson I, Velez R, Kristinsson SY, Landgren O, (2010) Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 28: 830-834.
5. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, et al. (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154: 32-75.
6. Law IP, Blom J, (1977) Second malignancies in patients with multiple myeloma. Oncology 34: 20-24.
7. Cuzick J, Erskine S, Edelman D, Galton DA, (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 55: 523-529.
8. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, et al. (1996) Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 95: 349-353.
9. The Finnish Leukaemia Group (2000) Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 65: 123-127.
10. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, et al. (2008) Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 111: 94-100.
11. Hasskarl J, Ihorst G, De Pasquale D, Schrottner P, Zerweck A, et al. (2011) Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 52: 247-259.
12. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, et al. (2011) Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118: 4086-4092.
13. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, et al. (2009) Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 144: 86-94.
14. Hirabayashi Y, Katanoda K, (2008) Comparison of time trends in multiple myeloma incidence (1973-1997) in East Asia, Europe and United States, from Cancer Incidence in Five Continents, Vols IV-VIII. Jpn J Clin Oncol 38: 720-721.
15. Landgren O, Weiss BM, (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23: 1691-1697.
16. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, et al. (2007) Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer 110: 896-905.
17. Rosner F, (1977) Secondary neoplasms in multiple myeloma. JAMA 237: 120.
18. Fenk R, Neubauer F, Bruns I, Schroder T, Germing U, et al. (2012) Secondary primary malignancies in patients with multiple myeloma treated with high-dose chemotherapy and autologous blood stem cell transplantation. Br J Haematol 156: 683-686.
19. Tsung-Mei C (2009) Taiwan's national health insurance system: High value for the dollar.Six countries, six reform models: Their healthcare reform, experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan; scientific W, editor. New Jersey: In: Okma KGH, Crivelli L, eds.
20. Rao JNK, Scott AJ, (1992) A simple method for the analysis of clustered binary data. Biometrics. 48: 577-585.
21. Moller H, Fairley L, Coupland V, Okello C, Green M, et al. (2007) The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer 96: 1484-1488.
22. Becker N, (2011) Epidemiology of multiple myeloma. Recent Results Cancer Res 183: 25-35.
23. Soong G (2011) Taiwan's future is 'super-aged': DOH. The China Post. Taipei.
24. Mannetje A, McLean D, Cheng S, Boffetta P, Colin D, et al. (2005) Mortality in New Zealand workers exposed to phenoxy herbicides and dioxins. Occup Environ Med 62: 34-40.
25. Gold LS, De Roos AJ, Brown EE, Lan Q, Milliken K, et al. (2009) Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol 33: 276-280.
26. Schwartz GG, (1997) Multiple myeloma: clusters, clues, and dioxins. Cancer Epidemiol Biomarkers Prev 6: 49-56.
27. Alberts SR, Lanier AP, (1997) Correspondence re: G. G. Schwartz, Multiple Myeloma: Clusters, Clues, and Dioxins. Cancer Epidemiol. Biomark. Prev., 6: 49-56, 1997. Cancer Epidemiol Biomarkers Prev 6: 857-858.
28. Chen HL, Liao PC, Su HJ, Guo YL, Chen CH, et al. (2005) Profile of PCDD/F levels in serum of general Taiwanese between different gender, age and smoking status. Sci Total Environ 337: 31-43.
29. Hsu JF, Chang YC, Liao PC, (2010) Age-dependent congener profiles of polychlorinated dibenzo-p-dioxins and dibenzofurans in the general population of Taiwan. Chemosphere 81: 469-477.
30. Kyle RA, Pierre RV, Bayrd ED, (1970) Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 283: 1121-1125.
31. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, et al. (1979) The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 301: 743-748.
32. Bouchardy C, Fernandez S, Merglen A, Usel M, Fioretta G, et al. (2008) Increased risk of second cancer among patients with ovarian borderline tumors. Gynecol Oncol 109: 210-214.
33. Rubino C, de Vathaire F, Diallo I, Shamsaldin A, Le MG, (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61: 183-195.
34. Lee KD, Chen SC, Chan CH, Lu CH, Chen CC, et al. (2008) Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev 17: 2647-2655.
35. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, et al. (2006) Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica 91: 1481-1488.
36. Landgren O, Thomas A, Mailankody S, (2011) Myeloma and second primary cancers. N Engl J Med 365: 2241-2242.
37. Allan JM, Travis LB, (2005) Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5: 943-955.
38. Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, et al. (2012) Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 26: 844-845.